– UK, Snaith – Croda International Plc (LON: CRDA) today announced the appointment of Nawal Ouzren to its Board as a non-executive director, effective from 1 February 2022.
“I am delighted to welcome Nawal to the Croda Board. Nawal’s deep understanding of the biotech industry and her strong P&L, operational management and manufacturing experience will be of great benefit to Croda. Nawal brings a truly international perspective to the Board, having lived, and worked in numerous countries throughout her career. Nawal’s appointment broadens our Board’s healthcare sector experience, cultural and geographical perspectives and management competences and ideas, and I am really pleased that our Board is now gender balanced,” commented Board Chairman, Anita Frew.
She added: “Her appointment builds on the existing Life Sciences knowledge and experience we have around the Board table in support of our strategic plans to deliver our ambition in these fast-growing markets.”
Nawal will also be appointed to the Audit, Nomination, and Remuneration Committees.
About Nawal Ouzren
Nawal Ouzren has 20 years of expertise across a wide range of business roles, including clinical development, operational and strategic management roles within the pharmaceutical industry. Nawal currently serves as CEO at Sensorion, a Euronext-listed biopharmaceutical company headquartered in France.
A chemical engineer by training, Nawal started her career at GE in operations management, manufacturing, and quality and then held executive roles at Baxter International, Baxalta, and the Shire before joining Sensorion in 2017.
Nawal brings with her first-hand experience in biologics and novel gene therapies and is a current serving non-executive director of Arena Pharmaceuticals, the US-headquartered biopharmaceutical company.
For more information: https://www.croda.com/en-gb
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.